Country: United States
Language: English
Source: NLM (National Library of Medicine)
METHENAMINE HIPPURATE (UNII: M329791L57) (METHENAMINE - UNII:J50OIX95QV)
Ingenus Pharmaceuticals, LLC
ORAL
PRESCRIPTION DRUG
Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. Methenamine preparations should n
Peach colored, capsule shaped, biconvex tablets debossed with "I" and "7"on one side and scoreline on two sides, free from mottled surface in bottles of 100 (NDC 50742- 142-01). Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Dispense in well-closed, light-resistant container with child-resistant closure. Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32811 Rx Only 553502 Revised: 01/2023
Abbreviated New Drug Application
METHENAMINE HIPPURATE- METHENAMINE HIPPURATE TABLET INGENUS PHARMACEUTICALS, LLC ---------- METHENAMINE HIPPURATE TABLETS, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Methenamine Hippurate Tablets, USP is a urinary tract antiseptic drug. Each peach color, capsule-shaped bi-convex tablet contains 1 g methenamine hippurate which is the hippuric acid salt of methenamine (hexamethylene tetramine). The tablet also contains inactive ingredients: FD&C Yellow No. 6, Magnesium Stearate, Colloidal Silicon Dioxide, Povidone, and Saccharin Sodium. STRUCTURAL FORMULA: ACTIONS MICROBIOLOGY Methenamine hippurate tablets have antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid, the other component, has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against _E. coli_, enterococci and staphylococci. _Enterobacter_ _aerogenes _is generally resistant. The urine must be kept sufficiently acid for urea- splitting organisms such as _Proteus _and _Pseudomonas _to be inhibited. _SUSCEPTIBILITY TESTING_ _FOR SPECIFIC INFORMATION REGARDING SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA_ _AND ASSOCIATED TEST METHODS AND QUALITY CONTROL STANDARDS RECOGNIZED BY_ _FDA FOR THIS DRUG, PLEASE SEE: HTTPS://WWW.FDA.GOV/STIC_ HUMAN PHARMACOLOGY Within 1/2 hour after ingestion of a single 1-gram dose of methenamine hippurate tablets antibacterial activity is demonstrable in the urine. Urine has continuous antibacterial activity when methenamine hippurate tablets are administered at the recommended dosage schedule of 1 gram twice daily. Over 90% of methenamine moiety is excreted in the urine within 24 hours after administration of a single 1-gram dose. Similarly, the hippurate moiety is Read the complete document